Logo of Medical Developments International (ASX:MVP)Latest Medical Developments International (ASX:MVP) News

Page 1
Page 1 of 2

Healthcare Wrap - Week 42 (12 Oct -> 16 Oct) 2026

Healthcare shares swung between sharp selling and early commercial progress this week, with EBR Systems falling 40.43% while Firebrick rose 13.79%.
Sales growth, clinical decisions and limited cash reserves remained the key tests for small healthcare companies.
Logan Eniac
17 Oct 2026

MVP CEO Brent MacGregor to step down as CFO takes interim role

Medical Developments International CEO Brent MacGregor is stepping down after six years, with CFO Anita James taking over as interim CEO from 15 October. The board has begun searching for a permanent successor as MacGregor prepares to return to North America.
Ada Torres
15 Oct 2026

Healthcare Wrap - Week 41 (5 Oct -> 9 Oct) 2026

Cynata led the week after launching a small capital raising, while Vitasora and Neurizon posted strong gains despite very different risks. Across healthcare, trial progress and regulator feedback competed with cash warnings and weaker share prices after trading gaps.
Logan Eniac
10 Oct 2026

Medical Developments turns stronger Penthrox demand into FY26 profit and cashflow

Medical Developments International returned to EBIT profitability in FY26 as Penthrox volumes strengthened across Australian hospitals and Europe. The company now faces the less glamorous test of converting regulatory progress into repeatable demand while absorbing weaker Respiratory sales and new amortisation costs.
Ada Torres
9 Oct 2026

Healthcare Wrap - Week 34 (17 Aug -> 21 Aug) 2026

Healthcare shares delivered a mixed week, with strong gains at AVITA Medical, Australian Clinical Labs and CSL despite very different company results.
Investors also weighed new US approvals, clinical trial progress, funding needs and rising sales across the sector.
Logan Eniac
22 Aug 2026

Medical Developments International Posts 9% Revenue Growth and 566% Profit Surge on Penthrox Expansion

Medical Developments International (ASX:MVP) reported a 9% revenue increase to $42.6 million and a 566% jump in net profit to $0.6 million for FY26, driven by robust growth in its Pain Management segment and expanded paediatric approvals in Europe.
Ada Torres
20 Aug 2026

Healthcare Wrap - Week 8 (16 Feb -> 20 Feb) 2026

Two capital raisings and one brutal reset set the tone, even as several companies posted clean growth or strong clinical updates. Radiopharmaceuticals kept delivering good news, but investors still punished supply-chain and cash needs fast.
Logan Eniac
21 Feb 2026

MVP Boosts Penthrox Sales Amid EBIT Challenges in FY26 H1

Medical Developments International (MVP) reported an 8% revenue increase driven by strong Penthrox growth, despite a slight EBIT loss impacted by foreign exchange. The company advances pediatric approvals and targets further volume gains.
Ada Torres
19 Feb 2026

Medical Developments Reports Positive Cashflow and Strong Penthrox Growth in H1 FY26

Medical Developments International has posted positive operating cashflow for the first half of FY26, driven by robust growth in its flagship product Penthrox across Australia and Europe, alongside progress in paediatric approvals.
Ada Torres
30 Jan 2026

Medical Developments International Boosts Penthrox Sales and Advances Paediatric Approval

Medical Developments International reported a strong start to FY26 with significant revenue growth driven by increased Penthrox volumes and pricing improvements in Australia, alongside steady European demand and progress on paediatric label approvals.
Ada Torres
10 Oct 2025

Medical Developments International Posts FY25 Profit Turnaround and Paediatric Approval

Medical Developments International has reported a remarkable turnaround in FY25, posting a net profit after tax and securing paediatric approval for its flagship product Penthrox in Europe.
Ada Torres
21 Aug 2025

Medical Developments International Posts 18% Revenue Growth, Returns to Profit

Medical Developments International Ltd reported an 18% increase in revenue to $39.1 million for FY25, returning to profitability with a net profit after tax of $0.1 million. The company advanced its Penthrox market expansion through regulatory approvals and new partnerships.
Ada Torres
21 Aug 2025